Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib vs chemotherapy in ALK-positive NSCLC after platinum
CTR20132969Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of crizotinib in ALK-positive non-small cell lung cancer, sponsored by Pfizer. Started May 2015; status: completed.
02
Drugs
crizotinib
03
Conditions
ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on CTR20132969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132969.